ArticleOncotarget2017

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study.

Qi Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.